YOLFTbeta
Immix Biopharma Inc

Immix Biopharma Inc

IMMX · NASDAQ · Healthcare / Biotechnology

7.84USD-0.23 (-2.85%)

Price History

Full chart

Market Stats

Previous Close8.07
Open8.25
Day Range7.66 – 8.38
52-Week Range1.99 – 15.10
Volume1.03M
Market Cap784.79M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.88
Dividend Yield0.00%
Beta0.20
50-Day Avg11.47
200-Day Avg9.03

About

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Ilya Rachman M.B.A., M.D., Ph.D.
  • Employees21
  • Headquarters11400 West Olympic Boulevard, Los Angeles, CA, United States, 90064, USA
  • Websitehttps://www.immixbio.com

Leadership

  • Dr. Ilya Rachman M.B.A., M.D., Ph.D.Co-Founder, CEO, Chief Scientific Officer & Chairman · b. 1973
  • Mr. Gabriel Morris B.A.President, CFO & Director · b. 1987
  • Dr. Vladimir P. Torchilin D.Sc., MSE, Ph.D.Scientific Co-Founder · b. 1947
  • Dr. Graham Ross FFPM, M.D.Chief Medical Officer & Head of Clinical Development · b. 1960
  • Dr. David Marks MBBS, Ph.D.Chief Medical Officer of Cell Therapy
  • Mr. Mel Davis-PickettHead of CMC Technical Development
  • Mr. Michael A. GrabowChief Commercial Officer

Financials

Income Statement

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue000-89.52M000
Growth (%)----+100.00%--
Cost of Revenue1.08K2.32K2.47K2.13K5.47K115.39K364.50K
Gross Profit-1.08K-2.32K-2.47K-89.52M-5.47K-115.39K-364.50K
Gross Margin---100.00%---
Operating Expense841.42K451.53K1.35M-81.30M16.14M22.56M29.59M
Operating Income-842.50K-453.85K-1.35M-8.22M-16.14M-22.67M-29.96M
Operating Margin---9.18%---
EBITDA-841.42K-451.53K-24.20M-8.22M-15.56M-21.54M-29.59M
EBITDA Margin---9.18%---
Net Income-972.81K-1.15M-24.38M-8.23M-15.43M-21.61M-29.44M
Net Income Margin---9.19%---
R&D583.16K248.15K126.53K4.20M8.74M11.29M16.26M
R&D as % of Total Revenue----4.69%---
Interest Expense109.98K101.98K179.85K4970--
Interest Expense % of Total Revenue----0.00%---

Balance Sheet

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets942.94K539.60K18.19M14.91M19.93M22.95M104.84M
Total Liabilities4.59M5.27M202.04K1.75M3.72M9.70M11.04M
Total Equity-3.65M-4.73M17.99M13.16M16.41M13.25M93.80M
Cash734.01K391.09K17.64M13.44M17.51M17.68M93.93M
Total Debt4.10M4.10M50.00K--1.07M1.07M
Net Debt3.37M3.71M-17.59M-13.44M-17.51M-16.61M-92.86M

Cash Flow

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-790.03K-404.69K-1.59M-7.41M-11.37M-14.60M-23.93M
Investing Cash Flow-7.31K-802-802--52.09K-1.18M-7.21M
Financing Cash Flow1.05M18.85M18.85M3.23M15.46M15.95M107.39M
Capital Expenditure7.31K4802352.09K1.18M732.92K
Free Cash Flow-797.34K-404.69K-1.59M-7.41M-11.42M-15.77M-24.66M
FCF to OCF100.93%100.00%100.05%100.00%100.46%108.07%103.06%

Earnings

Report DateMar 31, 2020Jun 30, 2020Sep 30, 2020Mar 31, 2021Jun 30, 2021Sep 17, 2021Dec 17, 2021Mar 28, 2022May 13, 2022Aug 12, 2022Nov 9, 2022Mar 27, 2023May 12, 2023Aug 11, 2023Nov 13, 2023Mar 29, 2024May 9, 2024Aug 12, 2024Nov 12, 2024Feb 26, 2025May 8, 2025Aug 8, 2025Nov 7, 2025Feb 25, 2026May 7, 2026Aug 7, 2026Nov 6, 2026
EPS Estimate0.000.000.000.000.000.000.00----0.11-0.22-0.14-0.17-0.23-0.23-0.23-0.21-0.16-0.25-0.23-0.16-0.19-0.15-0.21-0.17-0.18
EPS Actual-0.04-0.04-0.03-0.18-0.18-0.16-0.02-3.16-0.10-0.11-0.11-0.27-0.18-0.24-0.23-0.23-0.22-0.15-0.24-0.25-0.15-0.22-0.24-0.28-0.18-0.18-
Surprise-----------0.18%-22.73%-28.57%-41.18%0.00%0.00%4.35%28.57%-50.00%0.00%34.78%-37.50%-26.32%-86.67%14.29%-5.88%-
Timing-------After-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hours-After-hours-After-hours

Key Statistics & Ratios

Market Cap784.79M
Enterprise Value621.64M
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.00
Price / Book3.73
EPS-0.88
Book Value3.20
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-41.48M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-34.18%
Return on Assets-20.52%
Shares Outstanding71.54M
Shares Float56.17M
Beta0.20
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 1 analystsTarget 22.53
  • Buy
    1

Ownership Breakdown

Institutions
79.01%
Insiders
17.13%
Retail / Other
3.86%

Top Institutional Holders

  • HHG PLC
    4.80M6.75%
  • Saturn V Capital Management LLC
    4.66M6.54%
  • Eventide Asset Management, LLC
    3.89M5.47%
  • Deep Track Capital, LP
    2.77M3.90%
  • Opaleye Management Inc
    2.35M3.29%
  • Millennium Management LLC
    2.07M2.90%
  • Vanguard Capital Management, LLC
    1.79M2.51%
  • Marshall Wace Asset Management Ltd
    1.64M2.31%
  • Wellington Management Company LLP
    1.47M2.07%
  • Great Point Partners LLC
    1.28M1.79%
  • Velan Capital Investment Management LP
    1.08M1.52%
  • Bleichroeder LP
    1.00M1.40%
  • Logos Global Management LP
    1.00M1.40%
  • Franklin Templeton Inc
    969.07K1.36%

Top Fund Holders

  • Eventide Healthcare & Life Sciences I
    3.89M5.44%
  • State Street® SPDR® S&P® Biotech ETF
    2.22M3.10%
  • Janus Henderson Hrzn Biotec E2 USD
    1.95M2.72%
  • Vanguard MStar Total Stk Mkt Idx Invest
    1.78M2.49%
  • iShares Russell 2000 ETF
    1.05M1.47%
  • Columbia Small Cap Growth Inst
    749.61K1.05%